tirzepatide surmount SURMOUNT-1 Trial Summary: What Actually Showed ESC 2025: post-hoc SURMOUNT-5 data

parkeri or related SFG Rickettsia

Exenatide and liraglutide were released onto the market relatively early, whereas newer agents, such as lixisenatide, dulaglutide, and albiglutide, were approved more recently (Table 1)

The most common side effects of GLP-1 receptor agonists are gastrointestinal symptoms including nausea, vomiting, diarrhoea, and abdominal discomfort, particularly during treatment initiation

KPV: the leading peptide for psoriasis research If one peptide deserves the title of most promising for psoriasis research, it is KPV

This process magnifies the release of insulin and is dependent on the blood sugar level

Sleep difficulty in women at midlife: a community survey of sleep and the menopausal transition